Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease
Authors:
- 4 December 2023
- Vol. 82 (24) , 2296-2309
Abstract
No abstract availableKeywords
Funding Information
- NHLBI
- Bristol-Myers Squibb Company
This publication has 23 references indexed in Scilit:
- Heavy menstrual bleeding on Rivaroxaban ‐ Comparison with ApixabanBritish Journal of Haematology, 2016
- Challenges and Priorities for ResearchCirculation, 2014
- Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart DiseaseCirculation, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for WarfarinStroke, 2012
- Thrombotic Complications and Thromboprophylaxis Across All Three Stages of Single Ventricle Heart PalliationThe Journal of Pediatrics, 2012
- Antithrombotic Therapy in Neonates and ChildrenChest, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialThe Lancet, 2010
- Antithrombin activity in children with chylothoraxEuropean Journal of Cardio-Thoracic Surgery, 2006